Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Tandem Diabetes Care, Inc. (TNDM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
61.52+2.79 (+4.75%)
At close: 04:00PM EDT
61.60 +0.08 (+0.13%)
After hours: 05:31PM EDT
Advertisement
Sign in to post a message.
  • B
    Bobby
    @Tiara @Furry - you both have great insights. Thank you very much for sharing those! If you could be CEO for a day, what are the one or two items that you would like to get done?
  • F
    Furry
    Tandem plans full rollout of Mobile Bolus App in US by mid-July.
    Expected to be at no additional cost to all in-warranty X2 pump customers.
  • M
    M
    Tired of “rip out” sensors? Check out the Eversense XL
  • t
    terracin
    Yesterday's ~ 53.96 price/print just might of been a real gift. Still too early in this extremely volitile rate cycle to tell. However the street is saying they think its a gift today. I added, but am definitely under water on a small position. gl out there....
  • A
    ANTHONY
    In 6 months down $78.00 this administration is out of control
  • F
    Furry
    FDA has approved the Abbott FreeStyle Libre 3. The approval says the Libre 3 MARD is 7.8% with a 14-day wear time. Physical Libre 3 size is two US pennies stacked together.

    The Abbott FreeStyle has 4 Million world wide users. About 1/3 US and 2/3 OUS.

    BTIG analyst says according to FDA database the Libre 3 is factory calibrated and approved for integration with Automated Insulin Delivery (AID) systems.
  • F
    Furry
    Medtronic reports Full Year and Fourth Quarter Fiscal Year 2022 today.
    Diabetes: "US revenue declined in the high-twenties, given the absence of new product approvals."
    "We understand the root causes that impacted our performance and we're addressing them. Shortfall driven by supply chain (~75%), primarily in Surgical Innovation, China (~15%), and FX (~10%)."
    Furry: Laughing hysterically. Ok. Keep telling yourself that. Continuing....
    Medtronic Diabetes: "Grew high-teens sequential international on strength of MiniMed 780G and Guardian 4 Sensor"
    Furry: New product launch and that is the best you have? That is a joke - right?
    Medtronic Diabetes: Q4 FY22, Revenue (organic) negative 4.8% Y/Y down to $597M.
    Medtronic: "In active dialogue with FDA to successfully remediate quality findings detailed in the warning letter."
    Furry: Meaning Medtronic Diabetes USA is still in the penalty box. Where they belong.
    Medtronic Diabetes: FY22, Revenue (organic) negative 3.0% Y/Y down to $2338M.
    Medtronic changes the head of Diabetes. Again.

    Medtronic Q4 FY22 Revenue, USA is $213M (negative 27.3% Y/Y). That is for pumps, supplies and sensors. If you arbitrarily split that down the middle for pumps and sensors (Medtronic does not detail the results) you get $106.5M for pumps and pump supplies? Tandem reported $131.1M Revenue, USA in most recent report of First Quarter 2022. Looks to me like Tandem has now bypassed Medtronic Diabetes in the USA when factoring out the cgm portion of the Medtronic Diabetes business.

    Which leads one to the question: Why would anybody continue to use the 670g at this point when pretty much everybody knows that is a failed product?

    Find somebody (internationally) who is using the 780g AND who was previously using the 670g (in auto mode). Ask them what they think. Underwhelmed is a typical response. Wondering why it is almost the same. Feeling like they got ripped off and lied to maybe? Worth the effort if one likes to spend the time to investigate one's own investment choices.
  • F
    Furry
    Quote from MarketWatch:
    “Shares of DexCom Inc. (DXCM) surged 8.1% to pace the S&P 500's premarket gainers, after the diabetes care company said it was not currently in "active discussions" regarding a merger.”
  • A
    ANTHONY
    DXCM destroyed PODD stock today , down $22.00 . DXCM might be smart and change to TNDM . Ether way stay tuned for the accusations in this field .
  • F
    Furry
    Needham analysts consider the Medtronic diabetes and backbone divisions as possible spinoff choices for Medtronic.
    "Given its current underperformance, FDA warning letter, and totally different buyer base and gross sales channel from the remainder of MDT, we imagine that the diabetes enterprise ranks excessive on the checklist of potential portfolio strikes by MDT," Needham analysts mentioned. "Nevertheless, we notice that administration has hinted about vital pipeline packages in diabetes and we imagine that the enterprise has potential to change into accretive to MDT's total income development, so administration might select to proceed with the turnaround effort."
  • A
    Arthur
    This market has started to turn around I think. There will still be ups and down and some volatility for sure but I believe Wall Street has started buying again. As always they are ahead, while the rate is still going up and there’s still inflation. most likely they believe that the negative 1.5% GDP is definitely slowing the economy which in the future will result to lower inflation. Remember the FED has already been planning to raise rates upto September and could end up neutral after then or even reduction rates if we go on recession, to again stimulate the economy. The shorts will cover very soon as they know there’s only 4 months left and the bulls will be coming back again, WS knows this. Of course if you wait til Sep, obviously the price will be higher than today I believe. I’m all in today, Glta.
  • F
    Furry
    I am listening to the Tandem presentation with Piper Sandler now. Sheridan, Vosseller and Gasser are on with the Piper Sandler analyst, Matt O'Brien. Good conf so far. They kept Gasser quiet so far which is always a bonus. Analyst started with the obvious question of the potential Dexcom acquisition of Insulet and has now moved on to Tandem centric discussion. So far it all sounds good.
    Dexcom conf with Piper at 1:00 PM today (I think).
  • F
    Furry
    Abbott has a market cap of $200B with good earnings, dividends and cash flow.

    Abbott could buy Tandem, Ypsomed and Senseonics. Cheap pickup. The combined market cap of those three is only 85% of the ttm Levered Free Cash Flow from Abbott.

    Dexcom is currently in a good position where they are - without an Insulet acquisition.

    Why poke a stick at the sleeping giant bear?
  • F
    Furry
    On the Medtronic call this morning, Wells Fargo analyst Larry Biegelsen asked:
    "Just Geoff, on The Kidney Company news today, should we expect more like this? Or could they be more significant?"

    Earlier in the call, Medtronic CEO Geoff Martha had said:
    "Regarding portfolio management, we are continuing to advance the robust process we began talking about earlier this year. And within that, and as a smaller initial step, we're pleased to announce that we've reached an agreement where we will contribute our Renal Care Solutions business into a new company, which we will jointly own with DaVita. In return will receive up to $400 million in value from them and we expect this transaction will close in calendar 2023. The new company is going to develop a broad suite of novel kidney care solutions, including home-based products."

    In response to Larry's question, CEO Martha answered:
    "On the Renal Care Solutions joint venture with DaVita, this is what I'd characterize as a smaller initial step in terms of our portfolio management work. That work continues, and we do anticipate that there could be more portfolio moves over the course of FY '22. I'm not going to comment on the size of those. But I'd characterize this is a smaller initial step."

    Larry obviously had a reason for the question meaning he already had thoughts and ideas. It will be interesting to see if he expounds on his thoughts when he produces his writeup on Medtronic.
  • G
    Gopher
    Furry, do you know when the G7 is expected to be launched here?
  • t
    terracin
    Hello Tandem, I'm back in again. Back in the day we'd say "can't dance anyway...." when making/taking questionable actions. That said, it's "foot in the door" small position. Not sure where the market could bottom, and anything is possible going forward.
    The market is starting to discount a very different world. Hint; it's not Russia... oh, and get used to Cold Ward#2 there (think mutually asured destruction); it's China.... gl out there...
  • A
    Arthur
    Something is not right, the market is on a rally mode and this is at the 52 week lows. It wants to go up but someone is really pulling this down hard.
  • W
    WorldWasFlat
    $90 per share, i think dxcm, will get tndm and save $10B off the podd deal. CA funds will like that than the cross country affair.
  • J
    Jon
    What if dxcm and podd are just trying to save their share prices? We know earnings multiples are shrinking and dxcm and podd are way over priced vs Tndm.
  • A
    Arthur
    Looks like this stock has stabilized at this price regardless of whether the market is down big or not much. I think this has seen bottom, we’ll see.
Advertisement
Advertisement